Social Determinants of Health Simulation

By João L. Carapinha

November 1, 2023

PhRMA’s Social Determinants of Health

Let’s look into an insightful article by Kristin Williams, published on October 27, 2023. The piece shines a light on the structural barriers patients encounter when trying to access and afford medicines. Community-level factors strongly impact healthcare access, the research shows. Nearly 40% of US counties are pharmacy deserts! These shocking numbers highlight the difficulties many encounter in accessing drugs. The article then discusses PhRMA’s Social Determinants of Health (SDOH) simulation. This novel application lets users follow a patient’s journey and demonstrate how structural and social variables impact life-saving pharmaceutical access.

Better pharmaceutical access and adherence might save the U.S. $3.8 trillion in medical bills and lost productivity. It shows how much tackling healthcare inequality matters.

It appears that insufficient insurance coverage considerably affects care access. Though true for many, insurance alone isn’t a panacea. High out-of-pocket prices, complicated approval processes, and restricted prescription formularies are common even with coverage. Thus, while insurance is important, we must also address healthcare structural challenges.

Kristin Williams’ post challenges us to address healthcare’s structural barriers and promote a more fair system. We can create a healthy future in the US and other countries.

Reference url

Recent Posts

Advancing Collaborative TB Innovation to Tackle Drug Resistance

By João L. Carapinha

March 24, 2026

Collaborative TB Innovation is essential to ending the world’s deadliest infectious disease. Tuberculosis (TB) still claims millions of lives each year, with rising drug resistance, climate-driven migration, and conflict severely undermining global progress. While the burden falls heaviest on low...
Citation Analysis of Real-World Evidence in Medicare Drug Price Negotiations
Medicare Drug Price Negotiations are increasingly relying on real-world evidence, according to a new citation analysis of the first drugs selected under the Inflation Reduction Act. The study examined how the Centers for Medicare and Medicaid Services (CMS) uses real-world evidence (RWE) in its M...
Cost-Effectiveness of T1D Screening Effectiveness in Canadian Children

By João L. Carapinha

March 23, 2026

T1D screening effectiveness in the general population substantially outperforms targeted approaches based on family history or genetic risk, according to a new Canadian health economic analysis. General population autoantibody screening detects far more at-risk children than family-history or gen...